Neuropsychiatric Disease and Treatment最新文献

{"title":"Changes in Anxiety Severity and Acceptability of Venlafaxine in Generalized Anxiety Disorder in the United States: Results From a Real-World Study.","authors":"Christoph U Correll, Kannan Subramaniam, Pradeep Purushottamahanti, Bituparna Bayan, Luke A Bryden, Emily O C Palmer, Nadia Lipunova","doi":"10.2147/NDT.S608897","DOIUrl":"10.2147/NDT.S608897","url":null,"abstract":"<p><strong>Background: </strong>Anxiety disorders, including the common generalized anxiety disorder (GAD), are among the leading causes of disability globally. Clinical practice guidelines recommend venlafaxine, a serotonin and norepinephrine reuptake inhibitor, as a first-line pharmacological treatment option for GAD.</p><p><strong>Methods: </strong>This retrospective cohort study utilized longitudinal real-world data from the US-based database, Holmusk NeuroBlu Data, to explore anxiety severity changes following 30-90 days of venlafaxine prescription in adults with GAD. The main outcome was change from baseline (mean and median) in the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7) score, as well as clinically meaningful change (a difference of ≥4 points).</p><p><strong>Results: </strong>Of 756 patients with GAD (78.6% female, 78.4% White, mean [standard deviation] age 38.5 [14.4 years]), 71.8% had a diagnosis of comorbid major depressive disorder (MDD) at baseline and 23.0% had another anxiety/phobic disorder. Median (interquartile range [IQR]) GAD-7 scores decreased significantly (P<0.001) from 14.0 (10.0-18.0) at baseline (-30 to +7 days from first venlafaxine prescription) to 9.0 (5.0-14.0) points at follow-up (30-90 days after first venlafaxine prescription), a median (IQR) change of -3.0 (-8.0-0.0), corresponding to a shift from moderate to mild anxiety severity. Stratified by baseline anxiety severity, symptom improvement was more pronounced among patients with greater baseline severity. Overall, 48.1% of patients had a clinically meaningful decrease of ≥4 points in GAD-7 score, while only 7.5% significantly worsened. Altogether, 63.6% of patients continued venlafaxine for ≥90 days after first venlafaxine prescription.</p><p><strong>Conclusion: </strong>In this real-world cohort, improved GAD-7 scores were observed to be associated with venlafaxine prescription.</p>","PeriodicalId":19378,"journal":{"name":"Neuropsychiatric Disease and Treatment","volume":"22 ","pages":"608897"},"PeriodicalIF":3.2,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13361472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148437546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Random Forest-Based Risk Prediction Model for Non-Response to Methylphenidate in Children with Attention Deficit Hyperactivity Disorder.","authors":"Yuan Lei, Fang Li, Linyan Xiao, Chaolan Lei, Yunli Tang, Deng Zou","doi":"10.2147/NDT.S617475","DOIUrl":"10.2147/NDT.S617475","url":null,"abstract":"<p><strong>Objective: </strong>To develop and validate a prediction model based on the random forest algorithm to assess the risk of non-response to methylphenidate (MPH) in children with attention deficit hyperactivity disorder (ADHD), thereby providing decision support for individualized clinical treatment.</p><p><strong>Methods: </strong>A total of 150 children with ADHD who received MPH treatment were prospectively and consecutively enrolled. Based on changes in the Swanson, Nolan, and Pelham Rating Scale, Fourth Edition (SNAP-IV) scores after 3 months of treatment, patients were classified into a treatment response group (n = 116) and a non-response group (n = 34). Differences in clinical characteristics, pre-treatment clinical assessment scales, and laboratory parameters were compared. A random forest algorithm was used to construct the prediction model. Feature importance was evaluated based on the decrease in node impurity.</p><p><strong>Results: </strong>Serum 25-hydroxyvitamin D [25(OH)D], cortisol, S100β protein, brain-derived neurotrophic factor (BDNF), and urinary catecholamines were lower in the treatment non-response group. The combined subtype of ADHD, higher SNAP-IV total score, lower 25(OH)D levels, and lower dopamine levels were independent risk factors for non-response. In the random forest model, SNAP-IV score had the highest feature importance. The model, incorporating clinical characteristics, pre-treatment clinical assessment scales, and laboratory indicators, demonstrated excellent predictive performance in the test set (AUC=0.883; 95% confidence interval: 0.811-0.956) and an overall accuracy of 86.67%.</p><p><strong>Conclusion: </strong>The random forest-based prediction model can accurately identify children with ADHD who are unlikely to respond to MPH treatment.</p>","PeriodicalId":19378,"journal":{"name":"Neuropsychiatric Disease and Treatment","volume":"22 ","pages":"617475"},"PeriodicalIF":3.2,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13361829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148437526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Community Knowledge, Self-Reported Prevalence, and Management of Epilepsy in Lira District: A Descriptive Cross-Sectional Study.","authors":"Christopher Oneka Okullo, Rebecca Nakaziba","doi":"10.2147/NDT.S616816","DOIUrl":"10.2147/NDT.S616816","url":null,"abstract":"<p><strong>Background: </strong>Epilepsy is a chronic neurological disorder characterized by spontaneous, recurrent seizures affecting over 70 million individuals worldwide, irrespective of age, gender, or location. The burden is poorly documented in rural communities in Sub-Saharan Africa. People with epilepsy face social stigma, discrimination, and overall productivity losses. This study investigated self-reported prevalence, community knowledge, and the management approaches of epilepsy in Lira district, Uganda.</p><p><strong>Methods: </strong>A descriptive cross-sectional community -based study was conducted across the ten sub-counties of Lira District, employing random sampling among 400 adults, one per household. Data were collected using a pre-tested, interviewer-administered questionnaire translated into the local language (Leb Lango). Data was analyzed using SPSS v26, employing descriptive statistics (frequencies and percentages) and presented in form of tables and figures.</p><p><strong>Results: </strong>The majority (81%) of the 400 participants described epilepsy as a disease of sudden falling. 51.7% attributed it to severe malaria, and overthinking. While 54.8% reported having a close family member with epilepsy, the self-reported prevalence of the actual cases of epilepsy observed during the study was 25/400 (6.25%). Study participants reported symptoms such as black outs and sudden falls (91.8%) as well as convulsions (86.3%). Epilepsy onset was predominantly reported in childhood (42.5%). Most attacks occurred at no specific time (40.5%) or during moonrise/moonset (32.5%). 75% of respondents reported warning signs including dizziness (78.3%), palpitations (72.5%), and blurred vision (64.5%). Approximately 35% of families sought help from a hospital or herbalist, and 80% reported no improvement.</p><p><strong>Conclusion: </strong>This study documents a high self-reported prevalence and poor community management for epilepsy in Lira district. Community-based self-reports, rather than clinically verified findings, highlight the need for validated community screening programs, training of community health workers, strengthening of referral pathways, and supporting clinically validated prevalence studies.</p>","PeriodicalId":19378,"journal":{"name":"Neuropsychiatric Disease and Treatment","volume":"22 ","pages":"616816"},"PeriodicalIF":3.2,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13361471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148437599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of Post-Stroke Cognitive Impairment After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.","authors":"Fangjia Shen, Xijuan Guo","doi":"10.2147/NDT.S608599","DOIUrl":"10.2147/NDT.S608599","url":null,"abstract":"<p><strong>Background: </strong>Acute ischemic stroke (AIS) is frequently complicated by post-stroke cognitive impairment (PSCI), which significantly affects long-term prognosis and quality of life. However, the evidence regarding its risk factors remains inconsistent.</p><p><strong>Methods: </strong>A systematic search was conducted in PubMed, Embase, Cochrane Library, and Web of Science up to December 30, 2025. Observational studies evaluating risk factors for PSCI after AIS were included. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed- or random-effects models. Heterogeneity, sensitivity analyses, and publication bias were assessed.</p><p><strong>Results: </strong>Fifteen studies involving 30,022 participants were included. Age >75 years (OR = 1.07, 95% CI: 1.04-1.10), female sex (OR = 1.72, 95% CI: 1.41-2.10), diabetes (OR = 1.76, 95% CI: 1.29-2.40), elevated C-reactive protein (CRP; OR = 1.36, 95% CI: 1.14-1.62), and lower educational level (OR = 1.24, 95% CI: 1.12-1.38) were significantly associated with an increased risk of PSCI after AIS. Substantial heterogeneity was observed for some predictors, particularly age (<i>I²</i> = 89.9%) and educational level (<i>I²</i> = 89.6%).</p><p><strong>Conclusion: </strong>Several factors, including advanced age, female sex, diabetes, elevated CRP, and lower educational level, were associated with an increased risk of PSCI after AIS. These findings may support risk stratification and early monitoring strategies. However, the substantial heterogeneity observed for some predictors should be considered when interpreting the pooled estimates. Further prospective studies are needed to confirm these associations and clarify causal relationships.</p>","PeriodicalId":19378,"journal":{"name":"Neuropsychiatric Disease and Treatment","volume":"22 ","pages":"608599"},"PeriodicalIF":3.2,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13361418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148437593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Health-Related Quality of Life and Depression in Patients with Schizophrenia: The Mediating Roles of Oral Health Literacy and Oral Health-Related Self-Efficacy in a Cross-Sectional Structural Equation Analysis.","authors":"Xucong He, Xingxiao Huang, Jianzhong Cai, Huarong Zhou, Zhaodi Wang, Zhijun Lin, Cuiqiong He, Liting Liu, Zhibin Xie, Xiulan Liu, Yanheng Wei, Junfang Zeng, Junrong Ye, Aixiang Xiao","doi":"10.2147/NDT.S613904","DOIUrl":"10.2147/NDT.S613904","url":null,"abstract":"<p><strong>Background: </strong>The factors affecting depression in schizophrenia are complex and diverse and have been well reported in the literature. However, few studies have investigated the relationship and potential mediating pathways between oral health-related quality of life (OHRQoL), internal protective factors of oral health such as oral health literacy (OHL) and oral health-related self-efficacy (OH-SE) and depression in patients with schizophrenia. This study adopts structural equation model (SEM) to explore the hypothesized model of the interrelationship among OHRQoL, internal protective factors of oral health and depression in patients with schizophrenia.</p><p><strong>Methods: </strong>Patients with schizophrenia (n = 300) were conveniently recruited from a psychiatric hospital in China between September and November 2024, based on their availability and willingness to participate. Four validated self-report scales (Oral Health Impact Profile Scale (OHIP-14), Short-Form Health Literacy Dental Scale (HeLD-14), Self-Efficacy Scale for Self-Care (SESS), Self-Rating Depression Scale (SDS)) were used to collect data. We adopted SEM, mediation analyses and path analyses to explore the relationships among OHRQoL, OHL, OH-SE, and Depression.</p><p><strong>Results: </strong>The hypothesized model demonstrated acceptable model fit parameters: χ²/df = 1.721 (<i>P</i>< 0.001), root mean square error of approximation (RMSEA) = 0.049 (90% CI, 0.035-0.062), comparative fit index (CFI) = 0.975, goodness of fit index (GFI) = 0.939, adjusted goodness of fit index (AGFI) = 0.914. OH-SE and OHL mediated the influence of OHRQoL on depression, including a chain mediating effect where OHRQoL influenced depression through both OH-SE and OHL sequentially. Additionally, OH-SE mediated the relationship between OHRQoL and OHL, while OHL also mediated the effect of OH-SE on depression.</p><p><strong>Conclusion: </strong>This study provides novel evidence for the pathway OHRQoL → OH-SE → OHL → Depression. Clinicians may use this model as theoretical evidence to formulate targeted pathway-based interventions that enhance internal protective factors of oral health, which may improve OHRQoL while alleviating depressive symptoms, although causal inferences cannot be drawn from this cross-sectional study.</p>","PeriodicalId":19378,"journal":{"name":"Neuropsychiatric Disease and Treatment","volume":"22 ","pages":"613904"},"PeriodicalIF":3.2,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13364707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148448405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Drug Holidays on Metacognitive and Theory of Mind Skills of Children Diagnosed with Attention Deficit Hyperactivity Disorder: Preliminary Findings.","authors":"Merve Köksal, Mesut Sari, Yasemin İmrek, Yusuf Öztürk, Gonca Özyurt, Ali Evren Tufan","doi":"10.2147/NDT.S573124","DOIUrl":"10.2147/NDT.S573124","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the impact of summer drug holidays on metacognitive and theory of mind (ToM) skills in children with Attention-Deficit/Hyperactivity Disorder (ADHD) treated with methylphenidate (MPH).</p><p><strong>Methods: </strong>A naturalistic, prospective study was conducted at a child psychiatry outpatient clinic. Fifty-six treatment-naïve children or those restarting treatment after >6 months (aged 9-17, 76.8% male) with ADHD were enrolled. Participants were assessed at baseline, after two months of MPH treatment, and after a two-month summer drug holiday. Assessments included the Clinical Global Impressions-Severity (CGI-S) scale, the DSM-IV-Based Screening Scale for Disruptive Behavior Disorders (D-S-DBD), the Faux-Pas Test (FPT), the Test of Perception of Affect via Nonverbal Cues (TPANC), and the Metacognition Questionnaire for Children (MCQ-C). Attrition was high; only 12 children (21.4% of original sample) completed the full protocol. Analyses were conducted for both completers and the full sample using the Last Observation Carried Forward (LOCF) method.</p><p><strong>Results: </strong>MPH treatment significantly improved CGI-S, parent-rated hyperactive/impulsive and oppositional symptoms, and performance on FPT and affect perception tasks (all p<0.05). In the completer sample, the gains in ToM and affect perception were not significantly reversed after the two-month drug holiday. However, this finding is preliminary due to substantial attrition and limited statistical power. MCQ-C did not show significant change at any time point. Sensitivity analyses revealed that children lost to follow-up had higher baseline symptom and metacognitive problem scores, indicating potential selection bias.</p><p><strong>Conclusion: </strong>Methylphenidate treatment was associated with significant improvements in ADHD symptoms, ToM, and affect perception. The results highlight the need for larger, multi-center studies to reliably assess the impact of drug holidays on higher-order cognitive and social skills in ADHD.</p>","PeriodicalId":19378,"journal":{"name":"Neuropsychiatric Disease and Treatment","volume":"22 ","pages":"573124"},"PeriodicalIF":3.2,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in the Application of Brain-Computer Interface-Based Neurofeedback Training in the Rehabilitation of Patients with Major Depressive Disorder.","authors":"Junting Liu, Lingyu Liu, Han Chen, Shu Xuan, Xinke Leng","doi":"10.2147/NDT.S609788","DOIUrl":"10.2147/NDT.S609788","url":null,"abstract":"<p><p>Major depressive disorder is a highly prevalent affective disorder worldwide, and existing pharmacological and psychological treatments continue to demonstrate notable limitations in terms of therapeutic stability, adverse effects, and relapse prevention. Brain-computer interface-based neurofeedback training (BCI‑NFT) guides patients to actively regulate abnormal neural functional states through real‑time feedback of brain activity signals, thereby providing a precise interventional pathway that acts directly at the level of neural function. This narrative review examines the theoretical foundations, neural mechanisms, and clinical application modalities of BCI‑NFT in depression rehabilitation, encompassing advances in both non‑invasive and invasive neurofeedback technologies, diverse combined intervention paradigms, and the application prospects of a concurrent intervention approach integrating wearable BCI technology with aerobic exercise at the interdisciplinary intersection of sports neuroscience and psychiatric rehabilitation medicine. Preliminary evidence suggests that BCI‑NFT may facilitate neural functional recovery in patients with major depressive disorder through three primary mechanisms: remodeling of emotion‑regulation‑related brain regions, correction of aberrant EEG activity patterns, and improvement of large‑scale brain network connectivity; however, given the sample sizes and methodological heterogeneity of existing studies, these conclusions still require further validation through large-scale randomized controlled trials. Nevertheless, the widespread clinical implementation of BCI‑NFT remains constrained by a lack of standardized training protocols, insufficient clarity regarding suitable patient populations, and a paucity of large‑sample clinical data. Future research should, within a precision psychiatry framework and through the integration of multimodal neuroimaging and large‑scale randomized controlled trials, further advance the standardized clinical translation of BCI‑NFT.</p>","PeriodicalId":19378,"journal":{"name":"Neuropsychiatric Disease and Treatment","volume":"22 ","pages":"609788"},"PeriodicalIF":3.2,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13315852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148361599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Second-Generation Long-Acting Injectable Antipsychotics: A Comprehensive Assessment of Effectiveness, Safety, and Cost.","authors":"Petru Ifteni, Paula-Simina Petric, Andreea Violeta Popa, Andreea Teodorescu, Radu Georgescu, Mihnea Costin Manea","doi":"10.2147/NDT.S606817","DOIUrl":"10.2147/NDT.S606817","url":null,"abstract":"<p><strong>Background: </strong>Second-generation long-acting injectable antipsychotics (SG-LAIs) improve adherence, reduce relapse, and enhance outcomes in schizophrenia, yet remain underused. In Romania, data on psychiatrists' views is limited.</p><p><strong>Objective: </strong>To assess Romanian psychiatrists' attitudes and prescribing behaviors regarding SG-LAIs, and identify key drivers and barriers to their use.</p><p><strong>Methods: </strong>We conducted a cross-sectional questionnaire survey among psychiatrists in urban hospital, outpatient, and private settings, treating more than 1,000 patients with schizophrenia. The survey rated the four SG-LAIs available in Romania (aripiprazole, olanzapine, paliperidone, and risperidone) on efficacy, tolerability, dosing flexibility, monitoring needs, prescribing frequency, and perceived obstacles/facilitators.</p><p><strong>Results: </strong>80 psychiatrists participated. Aripiprazole LAI received the most favorable ratings, ranking highest for efficacy, safety, patient functioning, ease of administration, guideline alignment, side-effect profile, monitoring requirements, and overall preference. Paliperidone and risperidone were also positively evaluated for dosing versatility, whereas olanzapine generally scored lowest. Main factors encouraging LAI prescription were improved adherence (96.3%) and reduced relapse risk (96.3%), followed by a favorable clinical profile (66.3%). Key barriers included lack of patient trust (57.5%), lack of hospital supply (43.8%), absence of LAI formulations for certain antipsychotics (43.8%), and limited experience (36.3%).</p><p><strong>Conclusion: </strong>Romanian psychiatrists show a strong preference for aripiprazole LAI, with decisions driven mainly by clinical benefits. Reducing patient concerns and system-level limitations-especially availability, indications, and communication- may support increased use of SG-LAIs in everyday clinical care.</p>","PeriodicalId":19378,"journal":{"name":"Neuropsychiatric Disease and Treatment","volume":"22 ","pages":"606817"},"PeriodicalIF":3.2,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13295001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148345653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resting-State EEG Characteristics of Tardive Dyskinesia: Spectral and Network Connectivity Insights.","authors":"Linyuan Yan, Bingyan Xie, Yi Sun, Miao Zheng, JinJin Wang, Yuan Li, Jing Chen, Shiyu Zhou, Xin Yu, Junliang Yuan","doi":"10.2147/NDT.S595872","DOIUrl":"10.2147/NDT.S595872","url":null,"abstract":"<p><strong>Background and hypothesis: </strong>Tardive dyskinesia (TD) is an often irreversible movement disorder, mostly resulting from exposure to dopamine receptor antagonists. The electrophysiological characteristics of TD remain poorly understood. Resting-state electroencephalography (EEG) may help characterize frequency-specific cortical oscillatory and network alterations related to TD. We hypothesized that TD-related neurophysiological alterations may be reflected in cortical spectral power, hemispheric asymmetry, and large-scale functional connectivity.</p><p><strong>Study design: </strong>Resting-state EEG was recorded with a 32-channel system in 67 participants: 20 patients with TD, 25 patients without TD, and 22 healthy controls. Analyses focused on spectral power, hemispheric asymmetry, and functional connectivity measured using phase-lag index. Electrode-level spectral power analyses were corrected using the false discovery rate, and network-level connectivity differences were assessed using network-based statistics. Subgroup clinical association analyses within the TD group were considered exploratory.</p><p><strong>Study results: </strong>Compared with healthy controls, both TD and Non-TD patients showed increased theta relative power at central electrodes, including C4 and Cz, with group effects surviving false discovery rate correction. Cluster-based topographic analyses showed increased gamma2-gamma3 power over frontoparietal regions in TD patients and increased broadband gamma power over frontal-central regions in Non-TD patients relative to healthy controls. Within the TD subgroup, exploratory analyses showed nominal associations between hemispheric asymmetry indices and rapid medication withdrawal or duration of motor disorder, although these associations did not survive false discovery rate correction. Functional connectivity analyses identified frequency-specific network alterations, including reduced phase-locking value in the theta frequency band and reduced phase-lag index connectivity across alpha1, beta, and gamma frequency bands in TD-related comparisons.</p><p><strong>Conclusion: </strong>TD patients showed altered resting-state cortical oscillations and frequency-specific connectivity changes involving central, frontoparietal, and temporo-occipital networks. These findings provide preliminary electrophysiological evidence for cortical network involvement in TD and may inform future mechanistic studies. Given the modest sample size and exploratory nature of subgroup analyses, the findings should be interpreted cautiously and validated in larger longitudinal cohorts.</p>","PeriodicalId":19378,"journal":{"name":"Neuropsychiatric Disease and Treatment","volume":"22 ","pages":"595872"},"PeriodicalIF":3.2,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13292849/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148331721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Adjunctive Lumateperone 42 mg on Anhedonia and Across a Broad Range of Depressive Symptoms in Major Depressive Disorder: Post Hoc Analysis of a Phase 3, Randomized, Placebo-Controlled Trial.","authors":"Michael E Thase, Willie R Earley, Susan G Kozauer, Changzheng Chen, Hassan Lakkis, Suresh Durgam","doi":"10.2147/NDT.S594893","DOIUrl":"10.2147/NDT.S594893","url":null,"abstract":"<p><strong>Purpose: </strong>Lumateperone is a mechanistically novel Food and Drug Administration-approved antipsychotic to treat schizophrenia, depressive episodes associated with bipolar I and II disorder, and major depressive disorder (MDD). This analysis of the Phase 3, randomized, double-blind, placebo-controlled, multicenter Study 501 (NCT04985942) evaluated the broad efficacy of lumateperone across depression symptoms assessed by Montgomery-Åsberg Depression Rating Scale (MADRS) anhedonia factor and single-item scores.</p><p><strong>Patients and methods: </strong>Eligible adults (18-65 years) met DSM-5 criteria for MDD with inadequate response to 1 or 2 ADTs in the current depressive episode and had MADRS Total score ≥24, Clinical Global Impression-Severity score ≥4, and Quick Inventory of Depressive Symptomatology-Self-Report 16-item score ≥14. Patients were randomized to oral placebo or lumateperone 42 mg adjunctive to ADT for 6 weeks. A post hoc analysis assessed anhedonia symptoms according to MADRS anhedonia factor. MADRS Total score and MADRS anhedonia factor score were analyzed by baseline anhedonia factor score (median value: ≥18). A prospective analysis investigated change in individual MADRS items.</p><p><strong>Results: </strong>Lumateperone+ADT significantly improved anhedonia symptoms versus placebo+ADT at every visit according to MADRS anhedonia factor score (Day 43: least squares mean difference vs adjunctive placebo [LSMD], -2.5; effect size [ES], -0.50; <i>P</i><0.0001). In patients with baseline anhedonia scores equal to or more than the median, significant improvements in MADRS Total score (LSMD, -5.4; 95% CI, -7.21, -3.59; ES, -0.67; <i>P</i><0.0001) and anhedonia factor score (LSMD, -2.8; 95% CI, -3.91, -1.65; ES, -0.55; <i>P</i><0.0001) were observed for lumateperone+ADT versus placebo+ADT at Day 43, with significant between-group differences observed at all study visits. At Day 43, 9 of the 10 MADRS items significantly improved with adjunctive lumateperone compared with adjunctive placebo.</p><p><strong>Conclusion: </strong>Lumateperone 42mg+ADT significantly improved symptoms of anhedonia and a broad range of depression symptoms compared with placebo+ADT in patients with MDD with inadequate response.</p>","PeriodicalId":19378,"journal":{"name":"Neuropsychiatric Disease and Treatment","volume":"22 ","pages":"594893"},"PeriodicalIF":3.2,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13289650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148318454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}